[{"id":"202b854a-4f0b-4a92-acf1-e16644170e0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805371","created_at":"2023-04-10T14:03:01.614Z","updated_at":"2024-07-02T16:35:06.475Z","phase":"Phase 1","brief_title":"PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05805371","lead_sponsor":"City of Hope Medical Center","biomarkers":" PSCA","pipe":" | ","alterations":" PSCA Expression","tags":["PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PSCA Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-105"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/12/2024","start_date":" 06/12/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-05-02"},{"id":"0328902b-7f12-44fb-b4da-f0c7f9276495","acronym":"","url":"https://clinicaltrials.gov/study/NCT03873805","created_at":"2021-03-10T17:53:52.637Z","updated_at":"2024-07-02T16:35:07.197Z","phase":"Phase 1","brief_title":"PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03873805","lead_sponsor":"City of Hope Medical Center","biomarkers":" PSCA","pipe":" | ","alterations":" PSCA Expression","tags":["PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PSCA Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • MB-105 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 08/20/2022","primary_completion_date":" 08/20/2022","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-29"},{"id":"9a59caa8-c59f-4259-8127-f97b9ad829c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06193486","created_at":"2024-01-05T16:18:01.598Z","updated_at":"2024-07-02T16:35:14.838Z","phase":"Phase 1","brief_title":"Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC","source_id_and_acronym":"NCT06193486","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PSCA","pipe":"","alterations":" ","tags":["PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/26/2024","start_date":" 02/26/2024","primary_txt":" Primary completion: 01/13/2029","primary_completion_date":" 01/13/2029","study_txt":" Completion: 12/13/2033","study_completion_date":" 12/13/2033","last_update_posted":"2024-03-13"},{"id":"283266c0-98f1-4b60-833a-2384b5517207","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732948","created_at":"2023-02-17T15:00:52.460Z","updated_at":"2024-07-02T16:35:27.778Z","phase":"Phase 1","brief_title":"PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer","source_id_and_acronym":"NCT05732948","lead_sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","biomarkers":" PD-L1 • PSCA","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/02/2018","start_date":" 08/02/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-29"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"06698c8f-a572-49b2-938a-90cab93dc075","acronym":"","url":"https://clinicaltrials.gov/study/NCT02092948","created_at":"2021-04-06T07:52:33.222Z","updated_at":"2024-07-02T16:36:42.729Z","phase":"Phase 1","brief_title":"Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer","source_id_and_acronym":"NCT02092948","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PSCA","pipe":"","alterations":" ","tags":["PSCA"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 08/22/2013","start_date":" 08/22/2013","primary_txt":" Primary completion: 01/06/2017","primary_completion_date":" 01/06/2017","study_txt":" Completion: 01/06/2017","study_completion_date":" 01/06/2017","last_update_posted":"2020-07-27"},{"id":"c6bbab71-5678-4f57-b13f-81ebaa94a8e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03267173","created_at":"2021-01-18T16:08:14.684Z","updated_at":"2024-07-02T16:37:18.315Z","phase":"Phase 1","brief_title":"Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.","source_id_and_acronym":"NCT03267173","lead_sponsor":"First Affiliated Hospital of Harbin Medical University","biomarkers":" HER-2 • PSCA","pipe":"","alterations":" ","tags":["HER-2 • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mesothelin-targeted CAR-T immunotherapy"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 06/15/2017","start_date":" 06/15/2017","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2017-08-30"}]